Perspective · 10 Sep 2026
Conference abstractPublished 21 Jul 2016
Determining the mechanism and scope of a novel immunomodulatory peptide (C1) in Rheumatoid arthritis
Westmead Hospital, Australia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Rheumatoid arthritis (RA) is an autoimmune disease of unknown aetiology. The initial event is T-cell driven followed by macrophage infiltration leading to cytokine secretion, chronic inflammation and joint destruction. Most recent therapies therefore aim to neutralize key cytokines such as TNF or IL-6 and or inhibition of tyrosine kinases associated with T-cell signaling. We have developed a novel approach to inhibit the T-cell antigen mediated receptor (TCR) signaling by means of peptides. The initial key peptide termed Ã?¢Ã?Â?Ã?Â?core peptide, CPÃ?¢Ã?Â?Ã? derived from the transmembrane region of TCR-a chain that inhibits T-cell mediated responses in vitro and in vivo. To enhance the usage of CP as a therapeutic, D-amino acids and cyclization of peptide was carried out. The new peptide C1 was found to be more effective in treating arthritic rats than CP. Aim: To determine the effect of C1 on cytokine expression profile. Methodology: To understand the role of C1 in cytokine regulation we stimulated 2B4.11 hybridoma T-cell line and LK35.2, antigen presenting cells with pigeon cytochrome C (in an antigen presentation assay) in presence and absence of peptides. Cell free supernatants were assessed for secreted cytokine levels. Results & Conclusion: We observed that C1 and CP inhibited IL-2 production, key cytokine required for T-cell activation and proliferation. Along with this we also observed down regulation of inflammatory cytokines IL-6, TNF-a, and CCL5. However an interesting phenomenon observed was induction of IL-10 (regulatory cytokine) as a result of CP treatment; thereby suggesting a potential role of C1 and CP as new class of small molecule for treating inflammation. These are exciting possibilities with significant biological and therapeutic potential worthy of further investigation.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Limaye Amita”
- BylineArticles whose byline prints “Ali Marina”
- BylineArticles whose byline prints “Manolios Nicholas”
